![Relmada Therapeutics, Inc. logo](/logos/RLMD.webp)
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Overview | Financials
Company Name | Relmada Therapeutics, Inc. |
Symbol | RLMD |
Currency | USD |
Price | 2.4 |
Market Cap | 72,418,080 |
Dividend Yield | 0% |
52-week-range | 1.88 - 7.223 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD |
Website | https://www.relmada.com |
An error occurred while fetching data.
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD